CARsgen is a biopharmaceutical company with operations in China and the U.S. and is focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The Company has established a comprehensive CAR T-cell research and development platform, encompassing target discovery, innovative CAR T-cell development, clinical trials, and commercial-scale production.
CARsgen has internally developed a robust product pipeline with global rights. One of CARsgen’s lead candidates is zevorcabtagene autoleucel (“zevor-cel” or “CT053”), an autologous B-cell maturation antigen (BCMA) CAR T-cell product treating relapsed/refractory multiple myeloma (R/R MM). CT041, is an autologous CAR T-cell product candidate against the protein CLDN18.2, for the treatment of gastric cancer (GC), pancreatic cancer (PC), and other solid tumors. CT041 is the world’s first CAR T-cell candidate for the treatment of solid tumors that entered a confirmatory clinical trial.
To address major challenges of CAR T-cell therapies, CARsgen has also developed novel technologies and platforms, including:
1) CycloCAR®(Cytokine and Chemokine Loaded CAR), the next-generation technologies to increase efficacy in solid tumors;
2) THANK-uCAR®(Target and Hinder the Attack of NK cells on Universal CAR), a differentiated allogeneic CAR T platform;
3) LADAR®(Local Action Driven by Artificial Receptor), a versatile platform for precise targeting.
CARsgen has established a strong global presence and has been expanding its global manufacturing capacity in China and the U.S. to support clinical trials and commercialization. CARsgen has established in-house, vertically integrated manufacturing capabilities, including the production of plasmids, lentiviral vectors, and CAR T cells. With the clinical manufacturing facility in Xuhui, Shanghai and commercial current good manufacturing practices (CGMP) manufacturing facility in Jinshan, Shanghai, CARsgen manufactures CAR T-cell products in-house to support clinical trials in China and manufacture the lentiviral vectors in-house to support clinical trials globally. CARsgen’s RTP Manufacturing Facility, in the Research Triangle Park, Durham, North Carolina, the U.S., has started good manufacturing practices (GMP) production of autologous CAR T-cell products and successfully released the first GMP batch for the clinical trials in 2022.
The company's diverse team of experts collaborates across borders to advance the development of CAR T-cell therapies and ensure that they meet the needs of patients around the world.
CARsgen’s vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.